Elicio Therapeutics Inc. (ELTX)
NASDAQ: ELTX
· Real-Time Price · USD
5.38
-0.12 (-2.18%)
At close: May 05, 2025, 3:59 PM
5.35
-0.56%
After-hours: May 05, 2025, 03:59 PM EDT
-2.18% (1D)
| Bid | 4.33 |
| Market Cap | 85.83M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | -51.9M |
| EPS (ttm) | -4.25 |
| PE Ratio (ttm) | -1.27 |
| Forward PE | -2.02 |
| Analyst | Buy |
| Ask | 6 |
| Volume | 62,151 |
| Avg. Volume (20D) | 41,065 |
| Open | 5.67 |
| Previous Close | 5.50 |
| Day's Range | 5.38 - 5.67 |
| 52-Week Range | 3.34 - 11.45 |
| Beta | 0.93 |
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 32
Stock Exchange NASDAQ
Ticker Symbol ELTX
Website https://elicio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ELTX stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 76.58% from the latest price.
Stock Forecasts1 month ago
-19.64%
Elicio Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
3 months ago
-2.28%
Elicio Therapeutics shares are trading lower after the company announced a $10 million registered direct offering.
